Publications
Detailed Information
CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy : CKD-581 Downregulates Wnt/Beta -Catenin Pathway by DACT3 Induction in Hematologic Malignancy
Cited 2 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2022
- Publisher
- 한국응용약물학회
- Citation
- Biomolecules & Therapeutics, Vol.30 No.5, pp.435-446
- Abstract
- The present study evaluated the anti-cancer activity of histone deacetylase (HDAC)-inhibiting CKD-581 in multiple myeloma (MM) and its pharmacological mechanisms. CKD-581 potently inhibited a broad spectrum of HDAC isozymes. It concentration-dependently inhibited proliferation of hematologic cancer cells including MM (MM.1S and RPMI8226) and T cell lymphoma (HH and MJ). It increased the expression of the dishevelled binding antagonist of I3-catenin 3 (DACT3) in T cell lymphoma and MM cells, and decreased the expression of c-Myc and I3-catenin in MM cells. Additionally, it enhanced phosphorylated p53, p21, cleaved caspase-3 and the subG1 population, and reversely, downregulated cyclin D1, CDK4 and the anti-apoptotic BCL-2 family. Finally, administration of CKD-581 exerted a significant anti-cancer activity in MM.1S-implanted xenografts. Overall, CKD-581 shows anticancer activity via inhibition of the Wnt/I3-catenin signaling pathway in hematologic malignancies. This finding is evidence of the therapeutic potential and rationale of CKD-581 for treatment of MM.
- ISSN
- 1976-9148
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.